{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-076039","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.134394+00:00","generated_at":"2026-05-17T13:06:33.719554+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeuroOne Q3 revenue up 105% to $1.7M; net loss narrows to $1.5M; FY25 guidance reaffirmed","bullets":["Product revenue $1.7M, up 105% YoY; gross margin 53.9% (vs 34.1%).","Net loss $1.5M ($0.03 EPS) vs $2.8M ($0.10 EPS); operating expenses down 9% to $2.8M.","Oversubscribed $8.2M capital raise closed April 2025; cash $8.0M, no debt.","FY2025 product revenue guidance $8-10M (132-190% growth); gross margin guidance raised to 50-53%.","Milestones: FDA 510(k) filed for trigeminal ablation; first patient seizure-free 1-year; sEEG drug delivery order."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-076039","json":"https://secwatch.observer/filing/0001213900-25-076039.json","markdown":"https://secwatch.observer/filing/0001213900-25-076039.md","text":"https://secwatch.observer/filing/0001213900-25-076039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390025076039/0001213900-25-076039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390025076039/ea0252735-8k_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:06:33.719554+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}